Low-dose naltrexone plays antineoplastic role in cervical cancer progression through suppressing PI3K/AKT/mTOR pathway

被引：11
|
作者：
Liu, Ning [1 ]
Yan, Limei [1 ]
Shan, Fengping [2 ]
Wang, Xiaonai [2 ]
Qu, Na [3 ]
Handley, Mike K. [4 ]
Ma, Mingxing [5 ]
机构：
[1] China Med Univ, Shengjing Hosp, Dept Obstet & Gynecol, 36 Sanhao St, Shenyang 110004, Liaoning, Peoples R China
[2] China Med Univ, Dept Immunol, Coll Basic Med Sci, Shenyang North New Area, 77 Puhe Rd, Shenyang 110122, Liaoning, Peoples R China
[3] China Med Univ, Liaoning Canc Hosp & Inst, Canc Hosp, Dept Gynecol, 44 Xiaoheyan Rd, Shenyang 110042, Liaoning, Peoples R China
[4] Cytocom Inc, 37 North Orange Ave,Suite 607, Orlando, FL 32801 USA
[5] China Med Univ, Shengjing Hosp, Dept Gen Surg, 36 Sanhao St, Shenyang 110004, Liaoning, Peoples R China
来源：
TRANSLATIONAL ONCOLOGY | 2021年 / 14卷 / 04期
关键词：
Low-dose naltrexone; Cervical cancer; Proliferation; Invasion; PI3K; AKT; mTOR; EPITHELIAL-MESENCHYMAL TRANSITION; METASTASIS; SNAIL2; LDN;
D O I：
10.1016/j.tranon.2021.101028
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The incidence of cervical cancer is increasing annually worldwide. Low-dose naltrexone (LDN) has been reported to delay tumor progression, but the mechanism remains unclear. Here, we found that low-dose naltrexone could upregulate the expression of OGFr. Additionally, LDN could suppress the abilities of colony formation, migration and invasion in cervical cancer cells. LDN could also inhibit cervical cancer progression in mice model. Moreover, LDN indirectly reduced the expressions of PI3K, pAKT and mTOR in vitro and in vivo. Therefore, LDN may be considered a potential treatment option for cervical cancer.
引用
收藏
页数：8
相关论文
共 50 条
  • [21] PI3K/Akt/mTOR pathway as a target for cancer therapy
    Morgensztern, D
    McLeod, HL
    ANTI-CANCER DRUGS, 2005, 16 (08) : 797 - 803
  • [22] Targeting the PI3K/AKT/mTOR pathway in ovarian cancer
    Musa, Fernanda
    Schneider, Robert
    TRANSLATIONAL CANCER RESEARCH, 2015, 4 (01) : 97 - 106
  • [23] ACTL8 Promotes the Progression of Gastric Cancer Through PI3K/AKT/mTOR Signaling Pathway
    Yu, Wenhao
    Zhang, Qi
    Ali, Muhammad
    Chen, Bangquan
    Sun, Qiannan
    Wang, Daorong
    DIGESTIVE DISEASES AND SCIENCES, 2024, : 3786 - 3798
  • [24] SUGT1 regulates the progression of ovarian cancer through the AKT/PI3K/ mTOR signaling pathway
    Ke, Miao
    Xu, Jie
    Ouyang, Ye
    Chen, Junyu
    Yuan, Donglan
    Guo, Ting
    TRANSLATIONAL ONCOLOGY, 2024, 49
  • [25] PI3K/AKT/mTOR pathway in angiogenesis
    Karar, Jayashree
    Maity, Amit
    FRONTIERS IN MOLECULAR NEUROSCIENCE, 2011, 4
  • [26] The PI3K/Akt/mTOR signaling pathway
    Dennis, P. A.
    ANNALS OF ONCOLOGY, 2011, 22 : 19 - 19
  • [27] Overview of the PI3K/Akt/mTOR pathway
    Dennis, P. A.
    ANNALS OF ONCOLOGY, 2008, 19 : 21 - 21
  • [28] The PI3K/AKT/mTOR interactive pathway
    Ersahin, Tulin
    Tuncbag, Nurcan
    Cetin-Atalay, Rengul
    MOLECULAR BIOSYSTEMS, 2015, 11 (07) : 1946 - 1954
  • [29] Synaptopodin-2 plays an important role in the metastasis of breast cancer via PI3K/Akt/mTOR pathway
    Xia, Erjie
    Zhou, Xiaofen
    Bhandari, Adheesh
    Zhang, Xiaohua
    Wang, Ouchen
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 1575 - 1583
  • [30] PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment
    Angel Guerrero-Zotano
    Ingrid A. Mayer
    Carlos L. Arteaga
    Cancer and Metastasis Reviews, 2016, 35 : 515 - 524
12345